|

JAKi dose reduction strategy Clinical Trials

1 actively recruiting trial

Pipeline

Phase 4: 1

Top Sponsors

  • Sint Maartenskliniek1

Indications

  • Axial Spondyloarthritis (AxSpA)1
  • Rheumatoid Arthritis (RA1
  • Psoriatic Arthritis (PsA)1
  • Arthritis1

Other1 trial

REDO-JAK: Dose Reduction of Janus Kinase Inhibitors in Patients With Inflammatory Rheumatic Diseases
Phase 4

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.